Recombinant Human LRIG1 Protein, CF

Catalog # Availability Size / Price Qty
8504-LR-050
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
FAQs
Supplemental Products
Reviews

Recombinant Human LRIG1 Protein, CF Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by the ability of the immobilized protein to support the adhesion of BCE C/D‑1b bovine corneal endothelial cells. The ED50 for this effect is 0.5-2.5 μg/mL.
Source
Human embryonic kidney cell, HEK293-derived human LRIG1 protein
Human LRIG1
(Ala35-Ser779)
Accession # Q96JA1
HP GGGSGGGSGGGS HHHHHH
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Ala35
Predicted Molecular Mass
84 kDa
SDS-PAGE
91-120 kDa, reducing conditions

Product Datasheets

You must select a language.

x

8504-LR

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

8504-LR

Formulation Lyophilized from a 0.2 μm filtered solution in MES, NaCl and EDTA.
Reconstitution Reconstitute at 200 μg/mL in sterile water.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: LRIG1

LRIG1 is a 145 kDa leucine-rich repeat (LRR) and Ig-like domain-containing single-pass transmembrane glycoprotein. It has been shown to suppress tumor growth, regulate tissue homeostasis, and maintain stem cell quiescence (1-5). Human LRIG1 is synthesized with a 34 amino acid (aa) signal sequence, a 759 aa extracellular domain (ECD), a 21 aa transmembrane sequence, and a 278 aa cytoplasmic region. The LRIG1 ECD contains three C-type Ig-like domains as well as fifteen LRRs that are flanked by cysteine-rich regions (6, 7). The ECD of human LRIG1 shares 90% and 88% aa identity with the ECD of mouse and rat LRIG1, respectively. LRIG1 shares 45-50% aa identity with its mammalian paralogs, LRIG2 and LRIG3. LIRG1 is expressed widely throughout mouse and human tissues, including the liver, brain, stomach, small intestine, skeletal muscle, cornea, and hair follicle (3, 6, 8). LRIG1 functions as a tumor suppressor by controlling cell proliferation through the negative regulation of the EGF family of receptor tyrosine kinases. Specifically, the ECD of LRIG1 binds to EGF R, ErbB2, ErbB3, and ErbB4, inducing receptor ubiquitination and degradation (9, 10). LRIG1 expression, which is often dysregulated in human cancers, is a prognostic indicator of cancer development and relapse; decreased LRIG1 is associated with an increase in recurrence and mortality for a variety of cancers including breast, uterine, head-and-neck, glioma, prostate, and squamous cell (2, 11-13). Tissue homeostasis and stem cell dormancy is also thought to be modulated by the actions of LRIG1 on cell proliferation (14).

References
  1. Chang, L. et al. (2013) J. Exp. Clin. Cancer Res. 32:101.
  2. Lindquist, D. et al. (2014) Acta Oncol. 53:1135.
  3. Nakamura, T. et al. (2014) J. Clin. Invest. 124:385.
  4. Wang, Y. et al. (2013) Br. J. Cancer 108:1765.
  5. Jensen, K.B. and F.M. Watt (2006) Proc. Natl. Acad. Sci. U S A 103:11958.
  6. Guo, D. et al. (2004) Genomics 84:157.
  7. Jensen, K.B. et al. (2009) Cell Stem Cell 4:427.
  8. Suzuki, H. et al. (1996) J. Biol. Chem. 271:18981.
  9. Gur, G. et al. (2004) EMBO J. 23:3270.
  10. Laederich, M.B. et al. (2004) J. Biol. Chem. 279:47050.
  11. Johansson, M. et al. (2013) Neuro. Oncol. 15:1200.
  12. Thomasson, M. et al. (2003) Br. J. Cancer 89:1285.
  13. Thompson, P.A. et al. (2014) Cancer Res. 74:2928.
  14. Ordonez-Moran, P. and J. Huelsken (2012) EMBO J. 31:2064.
Long Name
Leucine-rich Repeats and Immunoglobulin-like Domains 1
Entrez Gene IDs
26018 (Human); 16206 (Mouse); 312574 (Rat)
Alternate Names
D6Bwg0781e; Img; LIG1; LIG-1; LRIG1

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human LRIG1 Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human LRIG1 Protein, CF and earn rewards!

Have you used Recombinant Human LRIG1 Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review